Filtered By:
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 1913 results found since Jan 2013.

Abstract 6: Treatment Effect of Clopidogrel Plus Aspirin Within 12 Hours of Acute Minor Stroke or TIA Session Title: Abstract Oral Session: Outcomes
Conclusions: Among patients treated within 12 hours, the combination of clopidogrel and aspirin was more effective than aspirin alone in reducing the risk of recurrent ischemic stroke during the 90-day follow-up and did not increase the hemorrhagic risk. The higher ischemic stroke rate in the initial hours after stroke supports early more aggressive antiplatelet therapy.Clinical Trial Registration-URL: http//www.clinicaltrials.gov. Unique identifier: NCT00979589.
Source: Circulation: Cardiovascular Quality and Outcomes - February 26, 2016 Category: Cardiology Authors: Li, Z., Wang, Y., Zhao, X., Liu, L., Xian, Y., Johnston, S. C., Wang, Y., the CHANCE Investigators Tags: Session Title: Abstract Oral Session: Outcomes Source Type: research

Systematic review and network meta-analysis of stroke prevention treatments in patients with atrial fibrillation.
CONCLUSION: All oral anticoagulants reduce the risk of stroke in AF patients. Some novel oral anticoagulants are associated with a lower stroke and/or major bleeding risk than warfarin. In addition to the safety and effectiveness of drug therapy, as reported in this study, individual treatment recommendations should also consider the patient's underlying stroke and bleeding risk profile. PMID: 27570467 [PubMed]
Source: Clinical Pharmacology: Advances and Applications - August 31, 2016 Category: Allergy & Immunology Tags: Clin Pharmacol Source Type: research

Oral antiplatelet and anticoagulant agents in the prevention and management of ischemic stroke.
Abstract Despite numerous advances over the last 50 years, stroke continues to be a leading cause of death and disability worldwide. The treatment and prevention of stroke has undergone extensive study, and significant advances in medical management have occurred within the past decade principally with the development of new classes of orally active anticoagulant drugs. Here we review these recent breakthroughs and the varying roles of anticoagulants and antiplatelet agents in the prevention and management of different ischemic stroke subtypes, as well as describe the benefits and ongoing challenges to incorporati...
Source: Current Pharmaceutical Design - December 20, 2016 Category: Drugs & Pharmacology Authors: Shrestha S, Coy S, Bekelis K Tags: Curr Pharm Des Source Type: research

The correlation between recurrent risk and CYP2C19 gene polymorphisms in patients with ischemic stroke treated with clopidogrel for prevention
Conclusion: For patients with IS treated with clopidogrel regularly for secondary prevention, poor metabolizer, and intermediate metabolizer patients had higher risk of recurrent stroke comparing with extensive metabolize ones. Carrying CYP2C19 LOF allele is an independent risk factor of stroke recurrence in patients with IS.
Source: Medicine - March 1, 2020 Category: Internal Medicine Tags: Research Article: Clinical Trial/Experimental Study Source Type: research

Aspirin Versus Clopidogrel Monotherapy for the Secondary Prevention of Recurrent Cerebrovascular Attack Following Previous Ischemic Stroke in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis
ConclusionClopidogrel monotherapy was neither inferior nor superior to aspirin monotherapy for the secondary prevention of recurrent cerebrovascular attack following previous ischemic stroke in patients with T2DM. Hence, clopidogrel or aspirin monotherapy is equally safe and effective in these patients with T2DM.
Source: Diabetes Therapy - March 26, 2020 Category: Endocrinology Source Type: research

Efficacy and Safety of Prasugrel by Stroke Subtype: A Sub-Analysis of the PRASTRO-I Randomized Controlled Trial.
CONCLUSIONS: Although statistical significance was not reached, the efficacy of prasugrel was potentially different between stroke subtypes, warranting further studies. PMID: 32493881 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - June 6, 2020 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Ponatinib-induced ischemic stroke in larval zebrafish for drug screening.
In this study, using Ponatinib as an inducer, we developed and characterized a zebrafish ischemic stroke model. This zebrafish ischemic stroke had the cerebral vascular endothelial injury, thrombosis, reduced blood flow, inflammation and apoptosis as well as the reduced motility. The zebrafish ischemic stroke model was validated with 6 known human therapeutic drugs of ischemic stroke (Aspirin, Clopidogrel, Naoxintong capsules, Edaravone, Xingnaojing injection, Shuxuening injection). The mRNA levels of the neovascularization-related gene (vegfaa) and vascular endothelial growth factor receptor gene (VEGFR), neurodevelopment...
Source: European Journal of Pharmacology - July 11, 2020 Category: Drugs & Pharmacology Authors: Zhu XY, Xia B, Ye T, Dai MZ, Yang H, Li CQ, Li P Tags: Eur J Pharmacol Source Type: research

Efficacy and Safety of Prasugrel vs Clopidogrel in Thrombotic Stroke Patients With Risk Factors for Ischemic Stroke Recurrence: A Double-blind, Phase III Study (PRASTRO-III)
CONCLUSIONS: We observed a risk reduction of 5% with prasugrel vs clopidogrel, indicating comparable efficacy. There were no major safety issues for prasugrel.PMID:35599000 | DOI:10.5551/jat.63473
Source: Journal of Atherosclerosis and Thrombosis - May 22, 2022 Category: Cardiology Authors: Takanari Kitazono Masahiro Kamouchi Yuji Matsumaru Masato Nakamura Kazuo Umemura Hajime Matsuo Nobuyuki Koyama Junko Tsutsumi Kazumi Kimura Source Type: research

Antithrombotic therapy for secondary prevention in patients with stroke or transient ischemic attack: A multiple treatment network meta-analysis of randomized controlled trials
ConclusionThe prognosis of patients with an ischemic stroke or transient ischemic attack is improved with antiplatelets. Cilostazol showed the best risk-benefit characteristics without trade-off with the risk of major bleeding. Improved stroke recurrence with intensified antiplatelet regimens is counterbalanced with higher bleeding risk, and consequently, mortality remains unaffected. Treatment decisions in stroke survivals should integrate the assessment of bleeding risk for better identification of patients with the highest benefit of treatment intensification. Systematic review registrationProspero registration number: ...
Source: PLoS One - August 17, 2022 Category: Biomedical Science Authors: D ániel Tornyos Source Type: research

Intracranial arterial stenosis and recurrence in stroke patients with different risk stratifications by Essen stroke risk score
CONCLUSION: ICAS was an independent predictor of both 3- and 12-month stroke recurrence in low-risk but not high-risk patients with minor ischemic stroke or transient ischemic attack according to ESRS stratification.PMID:37724803 | DOI:10.1080/01616412.2023.2257415
Source: Neurological Research - September 19, 2023 Category: Neurology Authors: Yue Suo Jing Jing Xia Meng Zixiao Li Yuesong Pan Hongyi Yan Yong Jiang Liping Liu Xingquan Zhao Yilong Wang Hao Li Yongjun Wang CHANCE investigators Source Type: research

Closing the Loop: A 21-year Audit of Strategies for Preventing Stroke and Death Following Carotid Endarterectomy.
The objective of this review was to identify causes of stroke/death after carotid endarterectomy (CEA) and to develop transferable strategies for preventing stroke/death after CEA, via an overview of a 21-year series of themed research and audit projects. Three preventive strategies were identified: (i) intra-operative transcranial Doppler (TCD) ultrasound and completion angioscopy which virtually abolished intra-operative stroke, primarily through the removal of residual luminal thrombus prior to restoration of flow; (ii) dual antiplatelet therapy with a single 75-mg dose of clopidogrel the night before surgery in additio...
Source: PubMed: Eur J Vasc Endovasc ... - June 13, 2013 Category: Surgery Authors: Naylor AR, Sayers RD, McCarthy MJ, Bown MJ, Nasim A, Dennis MJ, London NJ, Bell PR Tags: Eur J Vasc Endovasc Surg Source Type: research

The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: A meta-analysis of randomized controlled trials
Conclusions: Aspirin plus dipyridamole combination therapy was beneficial in reducing the recurrence of stroke, and did not increase the bleeding event. Hence, aspirin plus dipyridamole combination therapy is effective and safe for the secondary prevention of stroke.
Source: Journal of the Neurological Sciences - July 19, 2013 Category: Neurology Authors: Xia Li, Guoyu Zhou, Xueying Zhou, Shengnian Zhou Tags: Original Articles Source Type: research